Abstract Library

#1305 PRRT for Malignant Pheochromocytomas and Paragangliomas: The Singapore General Hospital Experience

Introduction: In recent years, the use of 177Lu-DOTATATE radioisotope therapy has been expanded to patients with metastatic pheochromocytomas and paragangliomas (PCC/PGL). Although this is not the standard of care, treatment options are limited for those with MIBG negative disease. Our centre has treated over 40 patients with NETS with PRRT since 2012.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author:

Authors: Loh L, Lim D, Loke K, Ng D,

Keywords: PRRT, pheochromocytoma, paraganglioma,

#1002 Retrospective Study of MIBG Therapy for Phaeochromocytoma (PH) and Paraganglioma (PG): The Christie Experience

Introduction: PH & PG are rare neuroendocrine tumors treated with MIBG but protocols are not standardized and reported results are variable.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Salih Z, Fletcher K, Clay V, Manoharan P, Hawkins R,

Keywords: mibg,

#941 Comparison of Radiolableled Somatostatin Analogues and (131) I-MIBG Treatment for the Management of Patients with Metastatic/Progressive Phaeochromocytomas and Paragangliomas

Introduction: Radionuclide therapy has been used to treat patients with progressive/metastatic paragangliomas (PGGs) and pheochromocytomas (PCCs). To date, there is no study comparing (131)I-MIBG and peptide receptor radionuclide treatment (PRRT) in those patients.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Nastos K, Toumpanakis C, Cheung V, Navalkissoor S, Quigley A,

Keywords: paraganglioma, pheochromocytoma, (131)I-MIBG, PRRT,

#880 Novel Succinate Dehydrogenase Subunit B Intronic Mutation in an Australian Kindred with Variable Clinical and Imaging Phenotype Necessitating Different Treatment Modalities Including 131-I MIBG and 177-Lutetium DOTATATE

Introduction: SDH B mutation has variable functional imaging phenotype challenging in terms of diagnosis, treatment modalities and follow-up.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Lee K, Conway L, Burge M, Wyld D, Macfarlane D,

Keywords: SDHB, Paraganglioma,

#662 Sequlae and Survivorship in Neuroendocrine Patients Treated with 131I-MIBG

Introduction: Radionuclide therapy in the form of 131I-MIBG has been in therapeutic use since the 1980s. Newer modalities are emerging for the treatment of neuroendocrine and chromaffin cell tumors, but many of these do not yet have adequate long-term follow-up to determine longer term efficacy and sequelae.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Sze C, Grossman A, Amendra D, Shieh S, Plowman N,

Keywords: neuroendocrine tumors, chromaffin cell tumors, radionuclide therapy, survival, long-term sequelae ,